Skip to main content
SpringerLink
Log in

Antidiabetika

  • Chapter
Arzneiverordnungs-Report 2001

Zusammenfassung

Ziele der Diabetestherapie sind Symptomfreiheit, Verbesserung der Lebensqualität und Vermeidung von Spätkomplikationen. Dieses wird nach den Daten mehrerer Studien durch eine möglichst optimale Blutzuckereinstellung erreicht. Für den Typ-1-Diabetes ist die Wirkung der Blutzuckereinstellung durch die DCCT-Studie gesichert (Diabetes Control and Complications Trial Research Group 1993). Für den Typ-2-Diabetes haben die Ergebnisse der UKPDS-Studie gezeigt, daß eine intensivierte Diabetestherapie mit einem HbA1c-Wert unter 7% über die ersten zehn Jahre nach der Diagnose die Häufigkeit mikrovaskulärer und — in geringerem Ausmaß — makrovaskulärer Komplikationen senkt (UK Prospective Diabetes Study Group 1998a, Stratton et al. 2000).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bailey C.J., Path M.R.C., Turner R.C. (1996): Metformin. New Engl. J. Med. 334:574–579.

    Article  PubMed  CAS  Google Scholar 

  • Berger M., Köbberling J., Windeier J. (1996): Wirksamkeit und Wertigkeit der Acar-bose.Dtsch. Ärztebl. 93: B-443–444.

    Google Scholar 

  • Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W. et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 121: 928–935.

    PubMed  CAS  Google Scholar 

  • Damsbo P., Clausen P., Marbury T.C., Windfeld K. (1999): A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789–794.

    Article  PubMed  CAS  Google Scholar 

  • De Fronzo R.A., Goodman M. (1995): Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New Engl. J. Med. 333: 541–549.

    Article  Google Scholar 

  • Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977–986.

    Article  Google Scholar 

  • Dills D.G., Schneider J. (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm. Metab. Res. 28: 426–429.

    Article  PubMed  CAS  Google Scholar 

  • Draeger K.E., Wernicke-Panten K., Lomp H.-J., Schüler E., Roßkamp R. (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm. Metab. Res. 28: 419–425.

    Article  PubMed  CAS  Google Scholar 

  • Dunn C.J., Peters D.H. (1995): Metformin A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721–749.

    Article  PubMed  CAS  Google Scholar 

  • Everett J., Kerr D. (1994): Changing from porcine to human insulin. Drugs 47: 286–296.

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., Heise T. (2000): Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644–649.

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L., Heise T. (2001): Klinische Wirkungen und Pharmakodynamik der Insulinanaloga lispro, aspart und glargin. Dtsch. Med. Wschr. 126: 597–604.

    Article  PubMed  CAS  Google Scholar 

  • Holman R.R., Mayon White V., Orde-Peckar C, Steemson J., Smith B. et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.

    Google Scholar 

  • Holman R.R., Cull C.A., Turner R.C. (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22: 960–964.

    Article  PubMed  CAS  Google Scholar 

  • Home P.D., Lindholm A., Riis A. (2000): Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 17: 762–770.

    Article  PubMed  CAS  Google Scholar 

  • Karam J.H., Etzwiler D.D. (eds.) (1983): International symposium on human insulin. Diabetes Care 6: 168.

    Google Scholar 

  • Koivisto V.A. (1998): The human insulin analogue insulin lispro. Ann. Med. 30: 260–266.

    Article  PubMed  CAS  Google Scholar 

  • Lalli C., Ciofetta M., del Sindaco P., Torlone E., Pampanelli S. et al. (1999): Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22: 468–477.

    Article  PubMed  CAS  Google Scholar 

  • Landgraf R,. Bilo HJ., Müller P.G. (1999): A comparison of repaglinide and gliben-clamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur. J. Clin. Pharmacol. 55:165–171.

    Article  PubMed  CAS  Google Scholar 

  • Landgraf R., Frank M., Bauer C., Dieken M.L. (2000): Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 24 (Suppl. 3): S38–44.

    Article  PubMed  Google Scholar 

  • Langtry H.D., Balfour J.A. (1998): Glimepiride. A review of its use in the management of Type 2 diabetes mellitus. Drugs 55: 563–584.

    Article  PubMed  CAS  Google Scholar 

  • Marbury T., Huang W.C., Strange P., Lebovitz H. (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43:155–166.

    Article  PubMed  CAS  Google Scholar 

  • McCall A.L. (2001): Clinical review of glimepiride. Expert. Opin. Pharmacother. 2: 699–713.

    Article  PubMed  CAS  Google Scholar 

  • Moses R. (2000): A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert. Opin. Pharmacother. 1: 1455–1467.

    Article  PubMed  CAS  Google Scholar 

  • Nathan D.M. (1998): Some answers, more controversy, from UKPDS. (Commentary). Lancet 352: 832–833.

    Article  PubMed  CAS  Google Scholar 

  • Olsson J., Lindberg G., Gottsater M., Lindwall K., Sjostrand A. et al. (2000): Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558–560.

    Article  PubMed  CAS  Google Scholar 

  • Phillips L.S., Grunberger G., Miller E., Padwardhan R., Rappaport E.B. et al. (2001): Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24: 308–315.

    Article  PubMed  CAS  Google Scholar 

  • Rosenstock J., Samols E., Muchmore D.B., Schneider J. (1996): Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19:1194–1199.

    Article  PubMed  CAS  Google Scholar 

  • Sachse G. (1994): Acarbose-Behandlung als neues Therapieprinzip. Dtsch. Ärztebl. 91, Suppl. 1517.

    Google Scholar 

  • Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E. et al. (2000): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit. Med. J. 321: 405–412.

    Article  PubMed  CAS  Google Scholar 

  • Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. (1995): Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl. J. Med. 333: 550–554.

    Article  PubMed  CAS  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.

    Article  Google Scholar 

  • Veneman T.F., Tack C.J., van Haeften T.W. (1998): The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe. Neth. J. Med. 52:179–186.

    Article  PubMed  CAS  Google Scholar 

  • Wilde M.I., McTavish D. (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.

    Article  PubMed  CAS  Google Scholar 

  • Wolffenbuttel B.H.R., Landgraf R. on behalf of the Dutch and German Repaglinide Study Group (1999): A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22: 463–467.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Hans-Georg Joost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Germany

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Joost, HG., Mengel, K. (2001). Antidiabetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56434-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56434-5_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42079-8

  • Online ISBN: 978-3-642-56434-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation